Mortality and Hospitalization Risks in Patients With Cancer and the SARS-CoV-2 Omicron Variant
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée à la COVID-19
JAMA Oncology, sous presse, 2023, résumé
Résumé en anglais
The SARS-CoV-2 Omicron variant, which is associated with milder disease than prior strains, became the dominant SARS-CoV-2 variant in November 2021. Research conducted before it became dominant demonstrated that patients with cancer had increased fatality rates from COVID-19 compared with patients without cancer; however, corresponding data on the Omicron variant are sparse.We compared the mortality and hospitalization rates among patients with vs without solid cancer and with a confirmed COVID-19 diagnosis during the Omicron-dominant period (December 2021 to September 2022).
